INT213917

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 11
Disease Relevance 8.68
Pain Relevance 0.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
brain 4
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 64 94.52 High High
agonist 5 68.84 Quite High
headache 13 5.00 Very Low Very Low Very Low
addiction 11 5.00 Very Low Very Low Very Low
cva 9 5.00 Very Low Very Low Very Low
Pain 9 5.00 Very Low Very Low Very Low
Bioavailability 6 5.00 Very Low Very Low Very Low
pruritus 6 5.00 Very Low Very Low Very Low
tolerance 6 5.00 Very Low Very Low Very Low
antagonist 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 410 100.00 Very High Very High Very High
Breast Cancer 380 100.00 Very High Very High Very High
Metastasis 73 100.00 Very High Very High Very High
Diarrhoea 104 98.52 Very High Very High Very High
Exanthema 79 97.96 Very High Very High Very High
Shock 4 96.96 Very High Very High Very High
Disease 189 94.84 High High
Apoptosis 141 89.28 High High
Carcinoma 2 83.52 Quite High
Immunotherapy Of Cancer 16 78.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In a preclinical model, lapatinib was shown to inhibit the formation of brain metastases in a breast cancer xenograft mode.32 In this murine model, lapatinib inhibited phosphorylation of EGFR, HER2 and associated downstream proteins.
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of HER2 in brain associated with breast cancer and metastasis
1) Confidence 0.54 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 1.40 Pain Relevance 0.45
Using a panel of 31 human breast tumors, Konecny et al. [41] showed that response to lapatinib was significantly correlated with HER2 expression and its ability to inhibit HER2, Raf, Akt, and ERK phosphorylation.
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of HER2 associated with breast cancer
2) Confidence 0.40 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.37 Pain Relevance 0.03
In a preclinical model, lapatinib was shown to inhibit the formation of brain metastases in a breast cancer xenograft mode.32 In this murine model, lapatinib inhibited phosphorylation of EGFR, HER2 and associated downstream proteins.
Negative_regulation (inhibited) of Phosphorylation (phosphorylation) of HER2 in brain associated with breast cancer and metastasis
3) Confidence 0.40 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 1.35 Pain Relevance 0.43
A phase I biomarker substudy, in which patients (n = 33) with various tumor types and various lapatinib doses provided a pre-treatment and a sequential Day 21 biopsy, allowed a pilot exploration of the impact of lapatinib on growth and survival pathways.49 Four patients with a PR had ErbB2 overexpression and high pre-treatment expression of phosphorylated (p) ErbB2, which was inhibited by lapatinib.
Negative_regulation (inhibited) of Phosphorylation (phosphorylated) of ErbB2 associated with cancer
4) Confidence 0.40 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.75 Pain Relevance 0
Tyrosine kinase inhibitors, such as emodin, which block HER-2 phosphorylation
Negative_regulation (block) of Phosphorylation (phosphorylation) of HER-2
5) Confidence 0.36 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.70 Pain Relevance 0
Tyrosine kinase inhibitors, such as emodin, which block HER-2 phosphorylation
Negative_regulation (such) of Phosphorylation (phosphorylation) of HER-2
6) Confidence 0.36 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.76 Pain Relevance 0
Tyrosine kinase inhibitors, such as emodin, which block HER-2 phosphorylation
Negative_regulation (as) of Phosphorylation (phosphorylation) of HER-2
7) Confidence 0.36 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.76 Pain Relevance 0
M had no effect on HER2 expression level or the degree of phosphorylation, and, when added to 1 ?
Negative_regulation (degree) of Phosphorylation (phosphorylation) of HER2
8) Confidence 0.27 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.41 Pain Relevance 0
Erlotinib inhibited tumour cell proliferation (Ki-67), and phosphorylation of EGFR and HER2.
Negative_regulation (inhibited) of Phosphorylation (phosphorylation) of HER2 associated with cancer
9) Confidence 0.26 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 1.33 Pain Relevance 0
Increased phosphorylation of ErbB2(Thr686), ErbB2(Ser1113) and limited phosphorylation of EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289) and ErbB4(Tyr1284) sites was seen in the control group.
Negative_regulation (limited) of Phosphorylation (phosphorylation) of ErbB2
10) Confidence 0.22 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.85 Pain Relevance 0
The addition of DHT to C-33 cells decreased PAcP expression and increased Her2 phosphorylation (Fig. 3A).
Negative_regulation (decreased) of Phosphorylation (phosphorylation) of Her2
11) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2812491 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox